经颈动脉血运重建与颈动脉内膜切除术的成本效益比较
本研究构建马尔可夫微观模拟模型,比较症状性颈动脉狭窄患者接受经颈动脉血运重建(TCAR)或颈动脉内膜切除术(CEA)的5年成本效益。结果显示CEA成本7821美元获得2.85质量调整生命年(QALY),TCAR成本19154美元获得2.92 QALY,增量成本效益比(ICER)为152229美元/QALY;TCAR在6年随访时具有成本效益。
要点
- 症状性患者TCAR的5年成本高于CEA,但QALY略高。
- TCAR的ICER为152229美元/QALY,概率敏感性分析中49%迭代具有成本效益。
- TCAR在6年随访时变为具有成本效益。
核心结论
- TCAR的5年成本高于CEA,但获得的QALY更多,TCAR在6年随访时具有成本效益。
研究设计与样本
- 马尔可夫微观模拟模型,使用现有文献的转移概率和效用值,纳入症状性颈动脉狭窄患者,成本转换为2019年美元,模型包含六个健康状态,周期长度为1个月,分析时间跨度为5年。
主要发现
- CEA成本7821美元获得2.85 QALY,TCAR成本19154美元获得2.92 QALY,ICER为152229美元/QALY。
- 敏感性分析显示模型对再狭窄概率、TCAR成本和CEA成本最敏感。
- 概率敏感性分析显示TCAR在49%的迭代中被认为具有成本效益。
关键数值与推荐
- CEA:成本7821美元,2.85 QALY;TCAR:成本19154美元,2.92 QALY;ICER为152229美元/QALY。
- TCAR在6年随访时具有成本效益。
临床怎么用
- 对于症状性颈动脉狭窄患者,选择TCAR或CEA时需考虑成本效益,TCAR在长期随访(6年)中可能更具成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recent studies have demonstrated that transcarotid artery revascularization (TCAR) has comparable outcomes to the surgical gold standard, carotid endarterectomy (CEA). However, few studies have analyzed the cost of TCAR, and no study has evaluated its cost-effectiveness. The purpose of this study is to conduct a cost-effectiveness analysis comparing TCAR with CEA for carotid artery stenosis. METHODS: We built a Markov microsimulation using transition probabilities and utilities from existing literature for symptomatic patients undergoing TCAR or CEA. Costs were derived from literature then converted to 2019 dollars. The model included six health states with monthly cycle lengths: surgery, death, alive after surgery, alive after myocardial infarction, alive after stroke, and alive after stroke and death. Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER) were analyzed over a 5-year period. One-way sensitivity and probabilistic sensitivity analyses were conducted to study the impact of parameter variability on cost effectiveness. RESULTS: For symptomatic patients, CEA cost $7821 for 2.85 QALYs, whereas TCAR cost $19154 for 2.92 QALYs, leading to an ICER of $152,229 per QALY gained in the TCAR arm. Sensitivity analysis demonstrated that our model was most sensitive to probability of restenosis, costs of TCAR, and costs of CEA. Probabilistic sensitivity analysis demonstrated TCAR would be considered cost-effective in 49% of iterations. CONCLUSIONS: This study found that, although 5-year costs for TCAR were greater than CEA, TCAR afforded greater QALYs than CEA. TCAR became cost-effective at 6 years of follow-up.
引用
- Cui C, Ramakrishnan G, Murphy J, et al. Cost-effectiveness of transcarotid artery revascularization versus carotid endarterectomy. J Vasc Surg. 2021. PMID: 34182030. doi:10.1016/j.jvs.2021.05.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。